Literature DB >> 24101545

Lymph node ratio and breast cancer prognosis: a meta-analysis.

Dechun Liu1, Yanbin Chen, Miao Deng, Gangqiang Xie, Jianguang Wang, Like Zhang, Qipeng Liu, Pengfei Yuan, Xiaoshan Feng.   

Abstract

Due to the heterogeneity of lymph node examination and the conflicting results existing for the same classification of lymph node ratio (LNR), it is necessary to conduct a meta-analysis to evaluate the prognostic effects of different LNRs on breast cancer. PubMed, EMBASE, and ISI Web of Knowledge were searched to find all published cohort studies that evaluated the prognostic value of different LNRs on breast cancer. The outcomes were overall survival (OS), disease-free survival (DFS), breast cause-special survival (BCCS), mortality, locoregional recurrence (LRR), and distant metastasis. Data was analyzed using comprehensive meta-analysis software version 2.0, and 23 studies were included. The available evidence showed that LNR was a prognostic predictor for breast cancer, especially for clinically node-positive breast cancer, but the available evidence could not judge which cutoff point is the most reliable. Meanwhile, the cutoff values 0.2 and 0.65 could be suitable to predict breast cancer OS, DFS, BCCS, and mortality.

Entities:  

Mesh:

Year:  2013        PMID: 24101545     DOI: 10.1007/s12282-013-0497-8

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  18 in total

1.  AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.

Authors:  Cornelia Liedtke; Marc Thill; Volker Hanf; Florian Schütz
Journal:  Breast Care (Basel)       Date:  2014-07       Impact factor: 2.860

Review 2.  A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma.

Authors:  M Elshaer; G Gravante; M Kosmin; A Riaz; A Al-Bahrani
Journal:  Ann R Coll Surg Engl       Date:  2016-11-21       Impact factor: 1.891

3.  Protein S100-A8: A potential metastasis-associated protein for breast cancer determined via iTRAQ quantitative proteomic and clinicopathological analysis.

Authors:  Jing-Min Zhong; Jing Li; An-Ding Kang; San-Qian Huang; Wen-Bin Liu; Yun Zhang; Zhi-Hong Liu; Liang Zeng
Journal:  Oncol Lett       Date:  2018-02-06       Impact factor: 2.967

4.  G protein-coupled estrogen receptor regulates mammary tumorigenesis and metastasis.

Authors:  Helen J Hathaway; Eric R Prossnitz; Nicole A Marjon; Chelin Hu
Journal:  Mol Cancer Res       Date:  2014-07-16       Impact factor: 5.852

5.  Recursive partitioning analysis of lymph node ratio in breast cancer patients.

Authors:  Yao-Jen Chang; Kuo-Piao Chung; Li-Ju Chen; Yun-Jau Chang
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

6.  Pathologic lymph node ratio is a predictor of esophageal carcinoma patient survival: a literature-based pooled analysis.

Authors:  Yuming Zhao; Shengyi Zhong; Zhenhua Li; Xiaofeng Zhu; Feima Wu; Yanxing Li
Journal:  Oncotarget       Date:  2017-07-15

7.  A Prognostic Model for Patients with Triple-Negative Breast Cancer: Importance of the Modified Nottingham Prognostic Index and Age.

Authors:  Jeanny Kwon; Keun-Yong Eom; Tae Ryool Koo; Byoung Hyuck Kim; Eunyoung Kang; Sung-Won Kim; Yu Jung Kim; So Yeon Park; In Ah Kim
Journal:  J Breast Cancer       Date:  2017-03-24       Impact factor: 3.588

8.  Lymph Node Ratio (LNR): Predicting Prognosis after Neoadjuvant Chemotherapy (NAC) in Breast Cancer Patients.

Authors:  Atilla Soran; Tolga Ozmen; Arsalan Salamat; Gürsel Soybir; Ronald Johnson
Journal:  Eur J Breast Health       Date:  2019-10-01

9.  Lymph Node Yield and Ratio in Selective and Modified Radical Neck Dissection in Head and Neck Cancer-Impact on Oncological Outcome.

Authors:  Sean C Sheppard; Lukas Frech; Roland Giger; Lluís Nisa
Journal:  Cancers (Basel)       Date:  2021-05-04       Impact factor: 6.639

10.  Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study.

Authors:  Se Hyun Kim; Kyung Hae Jung; Tae-Yong Kim; Seock-Ah Im; In Sil Choi; Yee Soo Chae; Sun Kyung Baek; Seok Yun Kang; Sarah Park; In Hae Park; Keun Seok Lee; Yoon Ji Choi; Soohyeon Lee; Joo Hyuk Sohn; Yeon-Hee Park; Young-Hyuck Im; Jin-Hee Ahn; Sung-Bae Kim; Jee Hyun Kim
Journal:  Cancer Res Treat       Date:  2016-03-23       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.